Emmaus Life Sciences board changes: George Sekulich resigns, Jon Kuwahara appointed

Emmaus Life Sciences, Inc.

George Sekulich resigned from board on Sep 30, 2024, after his termination as Chief Commercial Officer on Oct 4.
Jon Kuwahara appointed to fill vacancy effective Oct 1, 2024; also named Chair of Audit Committee.
Kuwahara served as Emmaus director from Jan 2016 to Sep 2018; now VP-Finance at Crinetics Pharmaceuticals (CRNX).
No family relationships or transactions requiring disclosure under Item 404(a) exist.
Kuwahara is a CPA with a BBA from University of Hawaii; prior roles at Novus Therapeutics and other life sciences firms.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jon Kuwahara

Director and Chair of Audit Committee

EMMA · Emmaus Life Sciences, Inc.

Effective: 2024-10-01
Filed: October 4, 2024, 7:59 PM ET

the Board appointed Jon Kuwahara to fill the resulting vacancy on the Board of Directors. The Board also appointed Mr. Kuwahara to serve as the Chair of the two-person Audit Committee.

Departed

George Sekulich

Director

EMMA · Emmaus Life Sciences, Inc.

Effective: 2024-09-30
Successor: Jon Kuwahara
Filed: October 4, 2024, 7:59 PM ET

On September 30, 2024, George Sekulich resigned as a member of the Board of Directors

Departed

George Sekulich

Chief Commercial Officer

EMMA · Emmaus Life Sciences, Inc.

Effective: 2024-10-04
Filed: October 4, 2024, 7:59 PM ET

in connection with the termination of his employment as our Chief Commercial Officer on October 4, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jon Kuwahara was appointed as Director and Chair of Audit Committee at Emmaus Life Sciences, Inc..

Action: appointed
Role: Director and Chair of Audit Committee

Exact text from the filing

the Board appointed Jon Kuwahara to fill the resulting vacancy on the Board of Directors. The Board also appointed Mr. Kuwahara to serve as the Chair of the two-person Audit Committee.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

George Sekulich resigned as Director at Emmaus Life Sciences, Inc..

Action: resigned
Role: Director

Exact text from the filing

On September 30, 2024, George Sekulich resigned as a member of the Board of Directors

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

George Sekulich was terminated as Chief Commercial Officer at Emmaus Life Sciences, Inc..

Action: terminated
Role: Chief Commercial Officer

Exact text from the filing

in connection with the termination of his employment as our Chief Commercial Officer on October 4, 2024

View on SEC.gov

Emmaus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-085641

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.